Influence of Tumor Burden on Serum Prostate-Specific Antigen in Prostate Cancer Patients Undergoing Radical Prostatectomy.
PSA
correlation
prostate cancer
prostate-specific antigen
radical prostatectomy
tumor weight
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
01
2021
accepted:
12
07
2021
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
17
8
2021
Statut:
epublish
Résumé
We aimed to assess the correlation between serum prostate-specific antigen (PSA) and tumor burden in prostate cancer (PCa) patients undergoing radical prostatectomy (RP), because estimation of tumor burden is of high value, e.g., in men undergoing RP or with biochemical recurrence after RP. From January 2019 to June 2020, 179 consecutive PCa patients after RP with information on tumor and prostate weight were retrospectively identified from our prospective institutional RP database. Patients with preoperative systemic therapy (n=19), metastases (cM1, n=5), and locally progressed PCa (pT4 or pN1, n=50) were excluded from analyses. Histopathological features, including total weight of the prostate and specific tumor weight, were recorded by specialized uro-pathologists. Linear regression models were performed to evaluate the effect of PSA on tumor burden, measured by tumor weight after adjustment for patient and tumor characteristics. Overall, median preoperative PSA was 7.0 ng/ml (interquartile range [IQR]: 5.41-10) and median age at surgery was 66 years (IQR: 61-71). Median prostate weight was 34 g (IQR: 26-46) and median tumor weight was 3.7 g (IQR: 1.8-7.1), respectively. In multivariable linear regression analysis after adjustment for patients and tumor characteristics, a significant, positive correlation could be detected between preoperative PSA and tumor weight (coefficient [coef.]: 0.37, CI: 0.15-0.6, p=0.001), indicating a robust increase in PSA of almost 0.4 ng/ml per 1g tumor weight. Preoperative PSA was significantly correlated with tumor weight in PCa patients undergoing RP, with an increase in PSA of almost 0.4 ng/ml per 1 g tumor weight. This might help to estimate both tumor burden before undergoing RP and in case of biochemical recurrence.
Identifiants
pubmed: 34395240
doi: 10.3389/fonc.2021.656444
pmc: PMC8358926
doi:
Types de publication
Journal Article
Langues
eng
Pagination
656444Informations de copyright
Copyright © 2021 Mandel, Hoeh, Preisser, Wenzel, Humke, Welte, Jerrentrup, Köllermann, Wild, Tilki, Haese, Becker, Roos, Chun and Kluth.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer. 2006 Jan 15;106(2):320-8
pubmed: 16342294
Clin Chem Lab Med. 2015 Jun;53(7):963-73
pubmed: 25581761
J Urol. 2004 Oct;172(4 Pt 1):1297-301
pubmed: 15371827
Urology. 2011 Oct;78(4):868-72
pubmed: 21843902
J Urol. 1993 Jul;150(1):100-5
pubmed: 7685416
J Urol. 1989 May;141(5):1076-83
pubmed: 2468795
Urology. 2010 Nov;76(5):1072-6
pubmed: 20846711
Clinics (Sao Paulo). 2008 Dec;63(6):759-62
pubmed: 19060997
Cancer. 1993 Feb 1;71(3 Suppl):933-8
pubmed: 7679045
Urology. 2007 Oct;70(4):711-6
pubmed: 17991542
J Urol. 1996 Jan;155(1):232-7
pubmed: 7490842
Eur Urol Focus. 2021 Jan;7(1):95-101
pubmed: 30905598
J Urol. 1998 Dec;160(6 Pt 1):2096-101
pubmed: 9817331
BMJ. 2018 Sep 5;362:k3519
pubmed: 30185521
N Engl J Med. 1987 Oct 8;317(15):909-16
pubmed: 2442609
Eur Urol. 2011 Aug;60(2):320-9
pubmed: 21458913
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Mod Pathol. 1997 Apr;10(4):326-33
pubmed: 9110294
PLoS One. 2019 Jun 13;14(6):e0218280
pubmed: 31194822
Prostate. 2008 Mar 1;68(4):373-80
pubmed: 18189231
BJU Int. 2012 Oct;110(7):942-8
pubmed: 22462566